1 / 19

Presenter Disclosure Information ISAR-REACT 2 Trial

One-year Clinical Outcomes in the ISAR-REACT 2 Trial, a Randomized Comparison of Abciximab Versus Placebo in Patients With non-ST Segment Elevation Acute Coronary Syndromes Undergoing PCI After Pretreatment With Clopidogrel.

buckminster-haney
Télécharger la présentation

Presenter Disclosure Information ISAR-REACT 2 Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. One-year Clinical Outcomes in the ISAR-REACT 2 Trial, a Randomized Comparison of Abciximab Versus Placebo in Patients With non-ST Segment Elevation Acute Coronary Syndromes Undergoing PCI After Pretreatment With Clopidogrel M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P. B. Berger, A. Schömig

  2. Presenter Disclosure InformationISAR-REACT 2 Trial Study performed without industry support The following potential of conflict exist related to this presentation: Seyfarth - Lecture fees from BMS, Lilly, Sanofi-Aventis: Modest level relationship Kastrati - Lecture fees from BMS, Lilly, Sanofi-Aventis: Modest level relationship Mehilli - No relationships to disclose Neumann - No relationships to disclose ten Berg - No relationships to disclose Bruskina - No relationships to disclose Dotzer - No relationships to disclose Pache - No relationships to disclose Dirschinger - No relationships to disclose Berger - Lecture Fees from Schering Plough and from CME: Modest level relationship Schömig - Unrestricted Grant from BMS and Nycomed: Modest level relationship

  3. ISAR-REACT 2 Multicenter, randomized, double-blind, placebo-controlled trial 2022 patients with NSTE-ACS Clopidogrel 600 mg at least 2h before procedure; Aspirin i.v. Abciximab Placebo • Heparin 70 U/Kg • Abciximab (bolus & 12h infus.) • Heparin bolus of 140 U/Kg • Placebo (bolus & 12h infus.) Clopidogrel 2x75 mg/day until discharge 75 mg for at least 4 weeks Aspirin 200 mg/day ISAR-REACT 2, JAMA 2006

  4. Rest anginal episodes in the last 48 hourswith An elevated troponin level (>.03 mg/L)or ST-segment depression ISAR-REACT 2: Inclusion Criteria ISAR-REACT 2, JAMA 2006

  5. ISAR-REACT 2: Exclusion Criteria • ST-elevation acute MI • Hemodynamic instability • Pericarditis • Increased risk of bleeding, malignancies • Relevant hematologic deviations • Known allergic reaction to the study medication • Pregnancy (present or suspected) ISAR-REACT 2, JAMA 2006

  6. A composite of death, MI or urgent target vessel revascularization within the first 30 days after PCI. ISAR-RACT 2: Primary End Point ISAR-REACT 2, JAMA 2006

  7. Primary Endpoint of ISAR-REACT-2 Death/MI/TVR 15 Placebo 11.9 % 10 Abciximab 8.9 5 P=.03 RR 0.75 [0.58-0.97] 0 0 5 10 15 20 25 30 Days after randomization ISAR-REACT 2, JAMA 2006

  8. to investigate whether benefits of abciximab are maintained at 1 year after PCI in patients with NSTE-ACS enrolled in the ISAR-REACT 2 trial. Objective of the present study

  9. Follow-Up Protocol 600 mg Clopidogrel PCI Abciximab vs. Placebo 0 30 d 6 mo 12 mo. serial CK + CKMB measurements clinicalfollow-up clinicalfollow-up clinicalfollow-up

  10. Baseline Clinical Characteristics Abciximab n=1012 Placebo n=1010 Age, yrs 66.0 ± 11.0 66.5 ± 11.3 Women, % 23.3 25.9 Hypercholesterolemia, % 61.6 60.3 Arterial hypertension, % 62.5 64.3 Diabetes mellitus, % 24.9 28.1 Current smoker, % 22.7 21.7 Body mass index, kg/m2 27.2 ± 3.9 27.3 ± 4.2

  11. Baseline Clinical Characteristics (con‘t) Abciximab n=1012 Placebo n=1010 Ejection fraction, % 53.3 ± 12.3 53.3 ± 12.5 Multivessel disease, % 74.4 74.3 Prior MI, % 24.2 24.1 Prior CABG, % 10.1 10.8 Elevated troponin, % 50.7 53.1

  12. Lesion Characteristics Abciximab n=1012 Placebo n=1010 Vessel LCA, % 2.4 2.2 LAD, % 41.9 40.4 LCx, % 23.8 26.0 RCA, % 28.1 26.2 Bypass graft, % 3.8 5.2 Complex (B2/C) lesions, % 80.2 81.2 DES, % 49.5 48.9 BMS, % 47.8 47.6 PTCA, % 2.7 3.5

  13. Primary Endpoint after 12 Months- Survival free of MI and TVR - 100 % 90 Abciximab 80 70 P=0.012 RR 0.80 [0.67-0.95] Placebo 60 50 0 1 2 3 4 5 6 7 8 9 10 11 12 Months after randomization

  14. Primary Endpoint after 12 Months- Survival free of MI - 100 Abciximab % 90 Placebo 80 70 P=0.015 RR 0.74 [0.59-0.94] 60 50 0 1 2 3 4 5 6 7 8 9 10 11 12 Months after randomization

  15. Subset Analyses Abciximab No./Total (%) Placebo No./Total (%) Relative Risk All Patients 281/1010 (28.0) 234/1012 (23.3) Age 159/527 (30.3) 128/482 (26.6) >67 years 122/483 (25.5) ≤67 years 106/530 (20.2) Sex 71/262 (27.4) Women 51/236 (21.7) 210/748 (28.2) Men 183/776 (23.8) Diabetes 80/284 (28.6) Yes 68/252 (27.1) 201/726 (27.8) 166/760 (22.0) No Troponin >0.03 g/L 178/536 (33.3) 146/513 (28.6) Yes 103/474 (22.0) 88/499 (17.8) No Clopidogrel interval 115/461 (25.1) >3 hours 93/475 (19.8) 166/549 (30.4) 141/537 (26.4) ≤3 hours 0.9 1.0 1.3 1.1 1.2 0.6 0.7 0.8 0.5

  16. Troponin Level and Benefit With Abciximab Death/MI/UTVR, % 20 Troponin-Positive: RR=0.71 [0.54-0.95] 15 Abciximab vs.Placebo 10 Troponin-Negative: RR=0.99 [0.56-1.76] 5 0 0 5 10 15 20 25 30 Days after randomization

  17. Troponin Level and Benefit With Abciximabafter 12 Months Troponin level ≤0.03 µg/L P=0.10 100 % 90 80 70 P=0.07 Abciximab Troponin level >0.03 µg/L 60 Placebo 50 0 1 2 3 4 5 6 7 8 9 10 11 12 Months after randomization

  18. Efficacy AnalysisAccording to Troponin Level Abciximab Placebo 17.1 18 16.8 15.5 % 13.8 13.2 12.7 12 6.7 6.6 5.1 4.6 6 2.7 2.2 0 Death MI TVR Death MI TVR Troponin level >0.03 µg/L Troponin level ≤0.03 µg/L

  19. The early benefit of Abciximab in patients with NSTE-ACS undergoing PCI after pretreatment with 600 mg Clopidogrel is maintained at 1 year after administration. Conclusions Another novel finding of this 1-year analysis is the additional benefit of Abciximab in low-risk patients without an elevated troponin in terms of a reduction of target vessel revascularization.

More Related